Targeted therapies: Last focus on EGF receptor inhibitors in breast cancer;Thérapies ciblées: Actualités sur les inhibiteurs des récepteurs à l'EGF dans le cancer du sein

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS. DEC., 2004, Pages

  Magné, Nicolas ^a,b   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; EGFR; Inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FULVESTRANT; GEFITINIB; RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MOLECULAR INTERACTION; NAUSEA; NEUTROPENIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; REVIEW; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTRADIOL; TAXOIDS;

EID: 12244297167     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Thompson DM, Gill GN. The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 1985; 4: 767-88.
2. Carpentet G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-12.
3. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988; 57: 443-78.
4. Yarden Y, Sliwkoski MX. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001; 2: 127-36.
5. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4): S9-S15.
6. Diéras V, Pierga JY, Vincent-Salomon A, Beuzeboc P, Pouillart P, De Cremoux P. Ciblage du récepteur du facteur de croissance épidermique dans les cancers du sein. Bull Cancer 2003; 90: S257-262.
7. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-facror receptor status as predicror of early recurrence of and death from breast cancer. Lancet 1987; 20: 1398-402.
8. Klijn JG, Berns PM, Scmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endoc Rev 1992; 13: 3-17.
9. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growrh factor receptor (EGFR) and irs relationship to the estrogen receptor status in 1029 patients wirh breast cancer. Breast Cancer Res Treat 2002; 71: 67-75.
10. Ferrero JM, Ramaioli A, Largillier R, Formenro JL, Francoual M, Ettore F, et al. Epidermal growth facror receptor expression in 780 breast cancer patienrs: a reappraisal of the prognostic value based on an eighr-year median follow-up. Ann Oncol 2001; 12: 841-6.
11. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003; 133: 219-21.
12. Bunone G, Briand P, Miksicek R, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-83.
13. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-24.
14. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-41.
15. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94.
16. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80: 239-56.
17. Arteaga CL, Truica CI. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 2004; 31(1 Suppl 3): 3-8.
18. Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs 2004; 8: 163-8.
19. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: 7; (abst. 23).
20. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Gonzalez S, et al. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancet. Proc Am Soc Clin Oncol 2003; 22: 7; (abst. 24).
21. Britten CD, Pegram M, Rosen P, Finn RS, Wax A, Bosserman LD, et al. Targeting EtbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer. Proc Am Soc Clin Oncol 2004; 23: 206; (abst. 3045).
22. Ciardiello F, Troiani T, Caputo F, De Laurentis M, Palmieri G, Marinelli A, et al. A phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2004; 23: 58; (abst. 725).
23. Dickler M, Rugo H, Caravelli J, Brogi E, Sachs D, Panageas K, et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004; 23: 127; (abst. 2001).
24. Schneeweiss A, Kolay S, Aulmann S, Von Minckwitz G, Torode J, Koehler M, et al. Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anticancer Drugs 2004; 15: 235-8.
25. Piccart M, Dochy E, Cardoso F. Actualités thérapeutiques dans le traitement médical du cancer du sein. Bull Cancer 2003; 90: 46-52.